References
- Weingart S, Brown E, et al. NCCN Task Force Report: Oral chemotherapy. J NCCN. 2008:6(Suppl 3):S1–S14
- Birner A. Safe administration of oral chemotherapy. Clin J Oncol Nurs. 2003;7:158–162.
- Osterberg L, Blaschke T. N Engl J Med. 2005;353:487–97.
- Cassidy J, Douillard DY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: The X-ACT trial. Br J Cancer. 2006; 94:1122–1129.
- Liu G, Franssen E, Fitch M, Warner E. Patient preference for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115.
- Partridge AH, Avorn J, Wong PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–66.
- Becker MH, Maiman LA, Kirscht JP, et al. The Health Belief Model and prediction of dietary compliance: A field experiment. J Health Soc Behav. 1977;18:348–366.
- Jasti S, Siega-Riz AM, Cogswell ME, et al. Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr. 2006;136:479–483.
- Bartel S. Safe practices and financial considerations in using oral chemotherapeutic agents. American Journal of Health-System Pharmacy. 2007;64(9): Suppl 51;p S8–S14.
- Aisner J. Overview of the changing paradigm in cancer treatment: Oral chemotherapy. American Journal of Health-System Pharmacy. 2007;64(9): Suppl 51;p S4–S7.
- Hartigan K. 2003 patient education: The cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003; 7(6): Suppl:21–24.